You have 9 free searches left this month | for more free features.

Myelodysplastic Syndromes

Showing 1 - 25 of 2,770

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

MDS Trial run by the National Cancer Institute (NCI) (decitabine and cedazuridine, BMS-986253)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Biospecimen Acquisition for Myelodysplastic Syndromes

Recruiting
  • Myelodysplastic Syndromes
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 20, 2022

    Relapsed / Refractory MDS Trial (NCR300)

    Not yet recruiting
    • Relapsed / Refractory Myelodysplastic Syndromes
    • (no location specified)
    May 7, 2022

    Interplay Between Immune and Metabolic Programs in

    Recruiting
    • Myelodysplastic Syndromes
      • Toulouse, France
        IUCT-Oncopole University Hospital
      May 17, 2022

      Mean Platelet Volume and Its Relation to Risk Stratification of

      Completed
      • Myelodysplastic Syndromes
        • (no location specified)
        Jan 21, 2022

        Low Risk MDS Trial (R906289 Monosodium (R289 Na))

        Not yet recruiting
        • Low Risk Myelodysplastic Syndromes
        • R906289 Monosodium (R289 Na)
        • (no location specified)
        Jul 22, 2022

        Acute Myeloid Leukemia, MDS Trial in Rochester (Inpatient serious illness care program)

        Not yet recruiting
        • Acute Myeloid Leukemia
        • Myelodysplastic Syndromes
        • Inpatient serious illness care program
        • Rochester, New York
          University of Rochester
        Jun 21, 2022

        MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)

        Terminated
        • MDS
        • Myelodysplastic Syndromes
        • APR-548 + Azacitidine
        • Tampa, Florida
        • +3 more
        Jul 20, 2022

        Clonal Cytopenia of Undetermined Significance, MDS Trial in Saint Louis (Atorvastatin, Rosuvastatin)

        Not yet recruiting
        • Clonal Cytopenia of Undetermined Significance
        • Myelodysplastic Syndromes
        • Saint Louis, Missouri
          Washington University School of Medicine
        Jul 28, 2022

        MDS Trial in Saint Louis (vosaroxin, Azacitidine)

        Active, not recruiting
        • Myelodysplastic Syndromes
        • Saint Louis, Missouri
          Washington University School of Medicine
        Mar 23, 2022

        Leukemias, MDS Trial in Houston (sapacitabine)

        Completed
        • Leukemias
        • Myelodysplastic Syndromes
        • Houston, Texas
          The University of Texas MD Anderson Cancer Center
        Dec 7, 2021

        MDS Trial (AG-946, Placebo)

        Not yet recruiting
        • Myelodysplastic Syndromes
        • (no location specified)
        Aug 4, 2022

        Recurrent/Refractory Acute Myeloid Leukemia, MDS Trial in ChengDu (TQB2618 injection azacitidine, AZA decitabine, DAC)

        Recruiting
        • Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
        • TQB2618 injection azacitidine, AZA decitabine, DAC
        • ChengDu, Sichuan, China
          West China Hospital of Sichuan University
        Jun 16, 2022

        MDS Trial in New York (selinexor (KPT-330))

        Completed
        • Myelodysplastic Syndromes
        • selinexor (KPT-330)
        • New York, New York
          Memorial Sloan Kettering Cancer Center
        Feb 11, 2022

        MDS Trial (Pevonedistat, Azacitidine)

        No longer available
        • Myelodysplastic Syndromes
        • (no location specified)
        Sep 8, 2021

        MDS, Myeloproliferative Tumors, Myelofibrosis Trial (Jaktinib, azacitidine)

        Not yet recruiting
        • Myelodysplastic Syndromes
        • +2 more
        • (no location specified)
        Nov 29, 2021

        MDS Trial in New Haven (CPX-351)

        Withdrawn
        • MDS
        • New Haven, Connecticut
          Yale University; Smilow Cancer Center
        Jan 6, 2022

        Lower-risk Myelodysplastic Trial in Tokyo (ASTX727)

        Active, not recruiting
        • Lower-risk Myelodysplastic
        • Tokyo, Japan
          NTT Medical Center Tokyo
        Jan 14, 2022

        MDS Trial in Bronx (Pyrimethamine)

        Withdrawn
        • Myelodysplastic Syndromes
        • Bronx, New York
          Montefiore Medical Center
        Sep 15, 2021

        Strategy for High-Risk Myelodysplastic Syndromes in Patients

        Active, not recruiting
        • Myelodysplastic Syndromes
        • Allogeneic Stem Cell Transplantation
        • Agen, France
        • +9 more
        Jul 5, 2022

        Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)

        Recruiting
        • Refractory Acute Myeloid Leukemia
        • +2 more
        • Cleveland, Ohio
          Cleveland Clinic, Case Comprehensive Cancer Center
        Mar 15, 2022

        MDS (MDS) Trial (Pevonedistat, Decitabine, Cedazuridine)

        Withdrawn
        • Myelodysplastic Syndromes (MDS)
        • (no location specified)
        Sep 23, 2021

        MDS Trial (Fasting-mimicking diet (FMD) and physiotherapy)

        Not yet recruiting
        • Myelodysplastic Syndromes
        • Fasting-mimicking diet (FMD) and physiotherapy
        • (no location specified)
        Jun 22, 2022

        MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)

        Not yet recruiting
        • Myelodysplastic Syndromes
        • Acute Myeloid Leukemia
        • (no location specified)
        May 24, 2022

        Physical Activity in Transfusion Dependent Myelodysplastic

        Recruiting
        • Myelodysplastic Syndromes
        • Medical Device Usage and Evaluation
        • +3 more
        • Philadelphia, Pennsylvania
          Sidney Kimmel Cancer Center at Thomas Jefferson University
        Aug 16, 2022